Company fully deploys 2021 work
Release time:
2021-02-10
Summing up Experience, Finding Problems, Formulating Measures
Company Fully Deploys 2021 Work
This newspaper reported that on February 1 and 2, the Group Company held a business work analysis meeting to review and summarize the work situation in 2020, arrange the deployment of the work for the new year, and put forward work requirements. At the
meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2020, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2021. The functional departments and offices of the headquarters made a brief report on the annual work situation and the 2021 work plan. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of each subordinate enterprise. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control management and bidding management in 2020; zhu Jianwei, Secretary of the Board of Directors, analyzed the future risks that the Company may encounter from the perspective of the securities market trends of listed companies in peak and related industries in 2020. Yu Jianhong, general manager of
Group Company, made a comprehensive review of the company's operation in 2020, made a comparative analysis of the main economic indicators of various industrial sectors, and pointed out that actively responding to the new coronary pneumonia epidemic has ensured the safety and health of all employees, made substantial progress in the construction of key investment projects, continuously strengthened management integration and improved management level, made new achievements in scientific and technological innovation and technological transformation, and made efforts to overcome the impact of expanding sales, innovative talent training, selection, and introduction forms, and effective improvement of corporate image, influence and reputation; at the same time, there is insufficient motivation for innovation and change, and the ideas and thinking methods of managers are still relatively traditional, conservative, and lack of pioneering spirit and crisis awareness. The gap between the comprehensive strength of the two main businesses and the competitiveness of some products and advanced enterprises in the industry is increasing, and the ability to develop new products is weak, the application of digital and intelligent technology is backward, and the work has some shortcomings such as superficial and formal phenomena to summarize and reflect.
After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong notified the 2021 benefit target set by the group company to various professional companies and directly affiliated enterprises, and proposed to follow the market law trend, achieve "five persistence", and fundamentally reverse the ideological concept of management cadres; Do a good job in project management, cultivate industrial advantages, and steadily promote development; Optimize the management system, strengthen management improvement and improve management efficiency; further strengthen technological innovation, increase investment in technological transformation, and promote the construction of "digital intelligence factory"; respect market laws, pay attention to user needs, and improve marketing capabilities; do a good job in management team building and further strengthen human resource development; Promote safety and environmental protection management to a new level; take party building as the guide, strengthen ideological and political work, enrich corporate cultural connotations, and create "soft power" for corporate competition "; we will continue to do a good job in the normal management of the prevention and control of the new crown pneumonia epidemic. In his concluding speech, Jiang Xiaomeng, chairman of
Group Company, expressed his affirmation and gratitude to all enterprises for their efforts and achievements in 2020. For future work, he asked the heads of subordinate enterprises to earnestly understand the spirit of the meeting, form a consensus, fully implement the company's various work arrangements and effectively promote them. Managers at all levels should strive to improve their ability to adapt to the changes of the times and achieve "the ability to find problems, there are ways to solve problems"; Establish a "3 3 N" way of thinking, that is, do a good job in the current work of sales, cost reduction, safety and environmental protection, plan the future development of forward-looking industrial layout, excellent products with market competitiveness, and capable excellent teams, and do a good job in the "N" related to the two "3; achieve both" visible management "such as labor discipline and work site and" invisible management "such as decision-making ability, charisma, and planning ability, so as to make enterprise management work smoother. Jiang Xiaomeng also hopes that all enterprises will increase the training and use of young backbones, better improve the combat effectiveness and work passion of the team, and all cadres and employees will work together to promote the better development of enterprises. (Reporter Fu Yiwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31